• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Sep 21, 2023
Emerging Company Profile

hC Bio: restoring protein function with tRNA therapies

Its sights set on cancer and rare diseases, Boston-based hC Bioscience hopes to take its first engineered tRNA therapy into the clinic next year 
Read More
BioCentury | Sep 12, 2023
Distillery Therapeutics

Targeting AHCY for APC-deficient CRC

Read More
BioCentury | Aug 27, 2021
Distillery Therapeutics

Inhibiting HOXC10 or its circular RNA stabilizer for colorectal cancer

Read More
BioCentury | Jan 11, 2020
Targets & Mechanisms

Colitis-associated somatic mutations yield new colorectal cancer target

Kyoto University suggests colitis-linked mutations may inhibit disease-associated colorectal cancer
Read More
BioCentury | Feb 28, 2019
Distillery Therapeutics

Cancer

Read More
BioCentury | Dec 4, 2014
Distillery Therapeutics

Indication: Cancer

Read More
BioCentury | Jun 26, 2014
Distillery Techniques

Technology: Drug delivery

Read More
BioCentury | Jul 25, 2013
Distillery Techniques

Technology: Disease models

Read More
BioCentury | Apr 18, 2013
Cover Story

Targeting tankyrase

Read More
BioCentury | Apr 15, 2013
Company News

Onyx, University Hospital, Howard Hughes Medical Institute, Johns Hopkins Oncology Center other research news

Read More
Items per page:
1 - 10 of 50